Subscribe to Neuroscience LISTSERV
What we know about aducanumab – the new FDA approved drug to treat Alzheimer’s disease
Wednesday, June 9, 2021
Earlier this week, the federal Food and Drug Administration (FDA) approved the use of the drug aducanumab to treat Alzheimer’s disease – making it the first new drug in nearly 20-years to treat the disease. Aducanumab is the first of a new generation of drugs that target the underlying damage in the brain. Anton Porsteinsson, M.D., is director of the Alzheimer’s Disease Care Research and Education Program (AD-CARE) at the University of Rochester Medical Center. He has spent the past ten plus years as the principal investigator of Biogen’s clinical trial for aducanumab at the Medical Center. And in the past year, he was hired as a consultant for Biogen to help with the Biologics License Application for aducanumab and testified before the FDA on the clinical findings of the drug. Findings he is hopeful will change how Alzheimer’s disease is evaluated and treated. Dr. Porsteinsson is also the William B. and Sheila Konar Professor of Psychiatry, Neurology, Neuroscience, and Medicine at the University of Rochester. We caught up with Dr. Porsteinsson to shared his incite about aducanumab and what it means for the disease that afflicts nearly six-million Americans.Read More: What we know about aducanumab – the new FDA approved drug to treat Alzheimer’s disease
Benjamin Suárez-Jiménez Receives Furth Fund Award
Thursday, May 6, 2021
The assistant professor of Neuroscience was among this year's awardees. The Furth Fund provides early career scientists with $12,500 in research funding.
Researchers find breastfeeding linked to higher neurocognitive testing scores
Monday, April 26, 2021
New research finds that children who were breastfed scored higher on neurocognitive tests. Researchers in the Del Monte Institute for Neuroscience at the University of Rochester Medical Center (URMC) analyzed thousands of cognitive tests taken by nine and ten-year-olds whose mothers reported they were breastfed, and compared those results to scores of children who were not.
“Our findings suggest that any amount of breastfeeding has a positive cognitive impact, even after just a few months.” Daniel Adan Lopez, Ph.D. candidate in the Epidemiology program who is first author on the study recently published in the journal Frontiers in Public Health. “That's what's exciting about these results. Hopefully from a policy standpoint, this can help improve the motivation to breastfeed.”
Hayley Martin, Ph.D., a fourth year medical student in the Medical Scientist Training Program and co-author of the study, focuses her research on breastfeeding. “There’s already established research showing the numerous benefits breastfeeding has for both mother and child. This study’s findings are important for families particularly before and soon after birth when breastfeeding decisions are made. It may encourage breastfeeding goals of one year or more. It also highlights the critical importance of continued work to provide equity focused access to breastfeeding support, prenatal education, and practices to eliminate structural barriers to breastfeeding.”
Researchers reviewed the test results of more than 9,000 nine and ten-year-old participants in the Adolescent Brain Cognitive Development (ABCD) study. Variations were found in the cumulative cognitive test scores of breastfed and non-breastfed children. There was also evidence that the longer a child was breastfed, the higher they scored.
“The strongest association was in children who were breastfed more than 12 months,” said Lopez. “The scores of children breastfed until they were seven to 12 months were slightly less, and then the one to six month-old scores dips a little more. But all scores were higher when compared to children who didn’t breastfeed at all.” Previous studies found breastfeeding does not impact executive function or memory, findings in this study made similar findings.
“This supports the foundation of work already being done around lactation and breastfeeding and its impact on a child’s health,” said Ed Freedman, Ph.D., the principal investigator of the ABCD study in Rochester and lead author of the study. “These are findings that would have not been possible without the ABCD Study and the expansive data set it provides.”Read More: Researchers find breastfeeding linked to higher neurocognitive testing scores
MRIs from Study by John Foxe & Ed Freedman Reveal More Incidental Findings in Children
Wednesday, March 24, 2021
Published in JAMA Neurology, scan results from the Adolescent Brain Cognitive Development (ABCD) Study revealed one in 25 children needed further medical evaluation. The findings by the Del Monte faculty members and their colleagues could change our understanding of the prevalence of neurological problems in children and how neuroimaging is used to screen for these problems.Read More: MRIs from Study by John Foxe & Ed Freedman Reveal More Incidental Findings in Children
An experimental neurofeedback imaging treatment has emerged for psychiatric patients. Does it work?
Monday, March 22, 2021
Does neurofeedback imaging work for psychiatric patients?
University of Rochester psychologists have found that real-time functional magnetic resonance imaging neurofeedback (rtfMRI-NF) can help a person regulate neural activity in a way that might improve psychiatric illness.
David Dodell-Feder, an assistant professor of psychology and neuroscience, together with Emily Dudek, who after graduating from Rochester became Dodell-Feder’s full-time lab manager, looked at 17 relevant studies that included a total of 410 participants. The findings of their meta-analysis have been published in the journal Neuroscience and Biobehavioral Reviews.
According to lead author Dudek, their review found that when people were shown their own brain patterns in real time, they were able to regulate activity in specific regions of the brain. “This training, known as neurofeedback, offers an exciting and novel treatment method for psychiatric illness.”
Coauthor Dodell-Feder agrees that the findings are “very promising,” especially because there are very few treatments, psychopharmacological included, that specifically target neural circuits known to contribute to psychopathology.
Yet, there are caveats: the data show less clear evidence that volitional control over the brain regions targeted by neurofeedback translates to an improvement in a person’s symptoms or cognitive impairments. For example, when analyzing the impact of rtfMRI-NF on symptoms, the team found an approximately 60 percent chance that a randomly selected person who received rtfMRI-NF showed improvement in symptoms compared to a randomly selected person who received a placebo procedure.Read More: An experimental neurofeedback imaging treatment has emerged for psychiatric patients. Does it work?
Andrew Anderson & Edmund Lalor Explore How Brain Comprehends Sentences
Monday, March 22, 2021
The Del Monte Institute faculty members and their colleagues studied and described the complex network within the brain that comprehends the meaning of a spoken sentence. The study, published in the Journal of Neuroscience, is an example of how the application of artificial neural networks, or A.I., is enabling researchers to unlock the extremely complex signaling in the brain that underlies functions such as processing language.Read More: Andrew Anderson & Edmund Lalor Explore How Brain Comprehends Sentences
Drs. Ania Majewska and Monique Mendes in a podcast for NINDS on F applications
Monday, March 1, 2021
Dr. Ania Majewska and NGP alum, Dr. Monique Mendes, will be featured in The National Institute of Neurological Disorders and Stroke’s Building Up the Nerve podcast on 3/5/2021. In this episode, our grantee guests discuss how they involved their mentor(s)/sponsor(s) in the application process to ensure the training plan reflects their individual needs and the mentor is able to provide the appropriate level of support and expertise to achieve those training goals.
The podcast features Jaroslaw Aronowski, PhD, Professor, UTHealth McGovern Med School; Alexis S. Mobley, MS, PhD Candidate, UTHealth McGovern Med School; Ania Majewska, PhD, Professor, University of Rochester; Monique Mendes, PhD, Postdoctoral Researcher, Stanford University; Mark Wu, MD, PhD, Professor, Johns Hopkins University; Margaret Ho, PhD, Postdoctoral Fellow, Johns Hopkins University School of Medicine.
Spread the word.Read More: Drs. Ania Majewska and Monique Mendes in a podcast for NINDS on F applications
Two faculty members received Sloan Awards for research on how the brain perceives the world.
Wednesday, February 17, 2021
Two University of Rochester researchers in the Department of Brain and Cognitive Sciences are being honored with a celebrated award for their contributions to and leadership in the scientific community.
Martina Poletti and Manuel Gomez-Ramirez, both assistant professors of brain and cognitive sciences and of neuroscience, are among this year’s recipients of Sloan Research Fellowships. Awarded annually by the Alfred P. Sloan Foundation since 1955, the fellowships recognize young scientists for their independent research accomplishments, creativity, and potential to become leaders in the scientific community. Each fellowship carries a $75,000, two-year award. This year, 128 scientists across the US and Canada were awarded fellowships. Gomez-Ramirez and Poletti are the University’s fourth and filth Sloan fellows in the last three years.Read More: Two faculty members received Sloan Awards for research on how the brain perceives the world.
Brain changed by caffeine in utero, study finds
Thursday, February 4, 2021
New research finds caffeine consumed during pregnancy can change important brain pathways in baby.
New research finds caffeine consumed during pregnancy can change important brain pathways that could lead to behavioral problems later in life. Researchers in the Del Monte Institute for Neuroscience at the University of Rochester Medical Center (URMC) analyzed thousands of brain scans of nine and ten-year-olds, and revealed changes in the brain structure in children who were exposed to caffeine in utero.
“These are sort of small effects and it’s not causing horrendous psychiatric conditions, but it is causing minimal but noticeable behavioral issues that should make us consider long term effects of caffeine intake during pregnancy,” said John Foxe, Ph.D., director of the Del Monte Institute for Neuroscience, and principal investigator of the Adolescent Brain Cognitive Development or ABCD Study at the University of Rochester. “I suppose the outcome of this study will be a recommendation that any caffeine during pregnancy is probably not such a good idea.”
Elevated behavioral issues, attention difficulties, and hyperactivity are all symptoms that researchers observed in these children. “What makes this unique is that we have a biological pathway that looks different when you consume caffeine through pregnancy,” said Zachary Christensen, a M.D/Ph.D. candidate in the Medical Science Training Program and first author on the paper published in the journal Neuropharmacology. “Previous studies have shown that children perform differently on IQ tests, or they have different psychopathology, but that could also be related to demographics, so it's hard to parse that out until you have something like a biomarker. This gives us a place to start future research to try to learn exactly when the change is occurring in the brain.”
Investigators analyzed brain scans of more than 9,000 nine and ten-year-old participants in the ABCD study. They found clear changes in how the white matter tracks – which form connections between brain regions – were organized in children whose mothers reported they consumed caffeine during pregnancy.
Researchers analyzed the brain scans of more then 9,000 nine and ten-year-olds and found a change in important brain pathways in those whose mothers retrospectively reported consuming caffeine while pregnant.
URMC is one of 21-sites across the country collecting data for the ABCD study, the largest long-term study of brain development and child health. The study is funded by the National Institutes of Health. Ed Freedman, Ph.D., is the principal investigator of the ABCD study in Rochester and a co-author of the study.
“It is important to point out this is a retrospective study,” said Foxe. “We are relying on mothers to remember how much caffeine they took in while they were pregnant.”
Previous studies have found caffeine can have a negative effect on pregnancy. It is also known that a fetus does not have the enzyme necessary to breakdown caffeine when it crosses the placenta. This new study reveals that caffeine could also leave a lasting impact on neurodevelopment.
The researchers point out that it is unclear if the impact of the caffeine on the fetal brain varies from one trimester to the next, or when during gestation these structural changes occur.
“Current clinical guidelines already suggest limiting caffeine intake during pregnancy – no more than two normal cups of coffee a day,” Christensen said. “In the long term, we hope to develop better guidance for mothers, but in the meantime, they should ask their doctor as concerns arise.”
Motion got you feeling queasy? It may be all in your head... or your ears
Friday, January 29, 2021
New research from the University of Rochester Medical Center has detailed a part of the nervous system by which the brain can modify our sense of balance. The current study expands our understanding of how balance stimuli are received by the brain while also offering insights into potential drug targets in the ear, which may be leveraged for treating motion sickness and balance disorders.
“In my opinion, these data are one of the first steps in beginning to unravel the functional significance of the efferent vestibular system,” Joseph C. Holt, Ph.D., senior author of the study published in the journal Scientific Reports said. The efferent vestibular system (EVS) begins as a small collection of neurons that travel from the brainstem out to the ear where our sense of balance begins. While there is still little known about the function of the EVS, URMC researchers are uncovering more about the role these neurons may play in processing motion stimuli and maintaining our balance.
Romanski Published in Neuron
Monday, January 11, 2021
"A View from the Top: Prefrontal Control of Object Recognition"
Object recognition occurs effortlessly. We easily name objects and recognize them as members of a class. We retrieve our knowledge about the properties of an object class and integrate that knowledge with goals to orchestrate our actions. Although object recognition seems automatic, easy, and rapid, the underlying computational problem that must be solved is daunting, and the neural mechanisms are correspondingly complex. The visual system must map many highly variable patterns of sensory input to one stable pattern of population activity at higher levels of the visual system constituting the neural code for the object’s identity. Despite changes in view, color, size, and orientation, the visual system recognizes the object. In neural terms, this means the system has found a “many-to-one” mapping, in the form of synaptic connections that allow many patterns of population activity at lower levels of the visual processing hierarchy (V1, for example) to propagate through sequential stages (V2 and above) in such a way that they converge onto, and recruit, a pattern of population activity at the top of the visual processing hierarchy, presumed to be inferotemporal cortex (IT), that corresponds to the object’s identity.Read More: Romanski Published in Neuron